Emma Andrus, Associate Editor

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Shi addresses one of the NEA's Eczema Awareness Month weekly themes, "Creative ways to manage your eczema."

Lio addresses one of the NEA's Eczema Awareness Month weekly themes, "What is eczema?"

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

This represents the second approval of Zoryve outside the US.

Forlenza addresses one of the NEA's Eczema Awareness Month weekly themes, "Tools for living your most ecz-pressive life with eczema."

The study represents the first to evaluate health care resource utilization among individuals with PN in England.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

Robb delved into how the system is transforming skin treatments with advanced precision, faster results, and improved patient outcomes.

Germany is now the first country to launch the topical treatment for adults with moderate to severe CHE.

Hui addresses one of the NEA's Eczema Awareness Month weekly themes, "Eczema is more than the visuals."

AbbVie's Eczema Experience Pop-Up event recently provided attendees with immersive insights into the physical and psychosocial toll associated with eczema.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss results of an open-label phase 3b/4 study for atopic dermatitis.

Light delves into the science behind the new peer-reviewed data assessing benzene presence and formation in benzoyl peroxide products.

New peer-reviewed research published in the Journal of Investigative Dermatology examined 111 products at room temperature.

Keep up with the latest headlines in dermatology from the past week, including anti-racism training for dermatology residents, the creation of artificial "smart skin," and more.

More than half of treatment responders maintained stable EASI ≤ 7, according to a poster from EADV.

A poster presented at EADV 2024 explored patient-reported outcomes from. the TRACE study for AD.

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Catch up on the latest news on vitiligo advancements in 2024.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Dermatology Times is recapping our top expert interviews from the month of September.

Keep up with the latest headlines in dermatology from the past week, including regulatory updates for bimekizumab and roflumilast, semaglutide and HS, and more.